ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.308,80
-0,95%
S&P 500
6.144,15
0,24%
US Dollar vs BRL
5,7233
0,03%
Bitcoin
97.239,37
0,63%
Brent Oil
75,47
-0,46%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Moleculin Biotech Inc (MBRX)

  7. Moleculin Biotech Inc (MBRX) Notícias

MBRX

Moleculin Biotech (MBRX)

Moleculin Biotech Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MBRX
DataHoraFonteTítuloCódigoCompanhia
13/02/202518:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/02/202515:05PR Newswire (US)Moleculin Announces Exercise of Warrants for $5.8 Million Gross ProceedsNASDAQ:MBRXMoleculin Biotech Inc
13/02/202511:25PR Newswire (US)Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
11/02/202510:40PR Newswire (US)Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal TrialNASDAQ:MBRXMoleculin Biotech Inc
11/02/202510:31Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
27/01/202514:08Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
27/01/202510:30PR Newswire (US)Moleculin Participates in Virtual Investor "What This Means" SegmentNASDAQ:MBRXMoleculin Biotech Inc
08/01/202510:30PR Newswire (US)Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026NASDAQ:MBRXMoleculin Biotech Inc
13/12/202419:02Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBRXMoleculin Biotech Inc
11/12/202410:00PR Newswire (US)Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML ModelNASDAQ:MBRXMoleculin Biotech Inc
10/12/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBRXMoleculin Biotech Inc
03/12/202419:20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MBRXMoleculin Biotech Inc
18/11/202410:15PR Newswire (US)New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNASDAQ:MBRXMoleculin Biotech Inc
14/11/202410:15PR Newswire (US)Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025NASDAQ:MBRXMoleculin Biotech Inc
12/11/202410:00PR Newswire (US)Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
11/11/202409:05PR Newswire (US)Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MBRXMoleculin Biotech Inc
08/11/202419:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBRXMoleculin Biotech Inc
06/11/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBRXMoleculin Biotech Inc
05/11/202411:00PR Newswire (US)Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
04/11/202410:30PR Newswire (US)Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
25/10/202417:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MBRXMoleculin Biotech Inc
17/10/202409:40PR Newswire (US)Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now AvailableNASDAQ:MBRXMoleculin Biotech Inc
07/10/202409:30PR Newswire (US)Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024NASDAQ:MBRXMoleculin Biotech Inc
04/10/202410:00PR Newswire (US)Moleculin to Present at Two Upcoming Investor ConferencesNASDAQ:MBRXMoleculin Biotech Inc
23/09/202409:00PR Newswire (US)Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of SarcomaNASDAQ:MBRXMoleculin Biotech Inc
16/09/202409:30PR Newswire (US)Moleculin Participates in Virtual Investor "What this Means" SegmentNASDAQ:MBRXMoleculin Biotech Inc
13/09/202417:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MBRXMoleculin Biotech Inc
13/09/202417:04Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
09/09/202409:15PR Newswire (US)Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of GlioblastomaNASDAQ:MBRXMoleculin Biotech Inc
03/09/202418:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MBRX

Seu Histórico Recente

USOTC
VLKAF
Volkswagen (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios